Congress designates September for sickle cell awareness, highlights gene therapy breakthroughs
S.Res. 416 — A resolution expressing support for the designation of September 2025 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease. · Filed by Tim Scott (R-SC) · 7 cosponsors · Introduced Sep 19, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This is a Senate resolution designating September 2025 as 'Sickle Cell Disease Awareness Month' to educate the public about sickle cell disease, a serious inherited blood disorder affecting approximately 100,000 Americans—disproportionately Black and Hispanic populations. The resolution encourages communities to hold events and programs raising awareness about the disease, early detection, treatments, and preventative care, and notes recent FDA approvals of gene therapies that can cure the condition.
Why we flagged it
This is a straightforward commemorative resolution designating a month for disease awareness. It contains no legislative mechanism, appropriation, or regulatory change—only a statement of support and encouragement for public education and community events.
What the text implies
- The resolution's emphasis on recent FDA-approved gene therapies and CMS's 'innovative cell and gene therapy access model' may indirectly signal support for expanded Medicaid coverage and reimbursement of expensive gene therapies, which could influence future policy discussions around drug pricing and access.
- By highlighting disparate disease burden (1 in 365 Black infants vs. 1 in 16,300 Hispanic infants), the resolution frames sickle cell disease as a racial health equity issue, which may strengthen future arguments for targeted research funding and health equity initiatives.
Who it affects
This resolution raises public awareness of a serious disease affecting a vulnerable population, highlights recent medical breakthroughs (gene therapies), and encourages preventative care and early detection—all of which benefit patients and their families. It carries no fiscal cost and no regulatory burden.
Who stands to gain
- gene therapy manufacturers
- pharmaceutical companies with approved sickle cell treatments
Named in the bill
Senate, Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), National Academies of Science, Engineering, and Medicine, Medicaid
Where it stands
7 cosponsors: 5 Democrats, 2 Republicans.
- Sep 19, 2025 — Passed the Senate · Congress.gov: “Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 6, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress designates September for sickle cell awareness, highlights gene therapy breakthroughs” QuorumCivic. https://share.quorumcivic.app/bill/119/sres416 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.